Improvement of a 'Leaky' Intestinal Barrier

Area of Science:

• Gastroenterology
• Immunology
• Microbiology

Background:

• Crohn's disease (CD) exhibits defective mucus layers with low defensin levels and reduced antibacterial activity, linked to disease localization.
• Ulcerative colitis (UC) presents with normal or increased defensin production but a compromised mucus layer that fails to retain antibacterial peptides.
• Both conditions result in a leaky antibacterial barrier, facilitating bacterial attachment and invasion, which triggers immune responses and tissue damage.

Purpose of the Study:

• To elucidate the distinct mucus barrier defects in Crohn's disease and ulcerative colitis.
• To explore potential therapeutic strategies targeting these primary barrier abnormalities in inflammatory bowel disease (IBD).

Main Methods:

• Comparative analysis of mucus layer characteristics and defensin levels in CD and UC.
• Review of existing and proposed therapeutic interventions for IBD targeting barrier function.

Main Results:

• CD is characterized by deficient defensins (alpha and beta) and poor mucus antibacterial activity.
• UC shows a structurally and chemically altered mucus layer that cannot retain antimicrobial peptides.
• Both defects lead to increased susceptibility to bacterial invasion and subsequent immune-mediated tissue destruction.

Conclusions:

• Therapeutic strategies for UC include probiotics or lecithin to stabilize mucus, with ongoing phase III trials.
• For CD, direct oral defensin application is a potential treatment, showing promise in experimental models.
• Addressing primary barrier defects in IBD may offer a valuable alternative to biologics, despite potentially slower relief.